Synbio International, Inc. (OTC: SYIN) announced on Tuesday that it has signed a strategic licensing, manufacturing, supply, and revenue sharing agreement with MD PHD Wellness, Inc. The deal grants Synbio exclusive rights to commercialize MD PHD Wellness’ proprietary nutraceutical formulations throughout the United States and Canada. This move is designed to accelerate Synbio’s path to revenue by leveraging an existing product pipeline rather than developing formulations from scratch.
The agreement covers MD PHD Wellness’ flagship anti-anxiety nutraceutical, which will be marketed under Synbio’s Healing Force™ brand. It also establishes a framework for evaluating and commercializing additional wellness products over time, creating a long-term product pipeline. Under the terms, MD PHD Wellness will handle product development, manufacturing, quality assurance, and supply chain management, while Synbio will focus on branding, marketing, sales, and distribution. Profits from product sales will be shared after recovery of approved manufacturing and commercialization costs.
“This agreement represents a transformational milestone for Synbio,” said Claudio Solitario, Chief Executive Officer of Synbio International. “Rather than building a nutraceutical business product by product, we have established a strategic partnership that combines MD PHD’s product development and manufacturing expertise with Synbio’s commercialization capabilities. It gives Synbio immediate access to proprietary products capable of generating near-term commercial revenue while establishing a framework to expand our wellness portfolio over time.”
The partnership is particularly significant given the rapid expansion of the global nutraceutical market. By gaining immediate access to scientifically developed products, Synbio positions itself to participate in this growth without the time and cost burden of in-house R&D. This approach allows management to focus on building brands, generating sales, and expanding market presence, which are critical for shareholder value creation.
MD PHD Wellness brings notable scientific leadership to the table. Co-founder Dr. Robert Lawrence is a physician, scientist, and inventor with two Ph.D.s in Nuclear Physics and Biomedical Engineering. His career spans medicine, biomedical engineering, microbiology, pharmacology, and nutraceutical development, with research in cellular regeneration and natural product delivery systems. Co-founder Dr. David Anderson, an experienced physician and researcher, played a key role in developing the licensed formulations. He has extensive expertise in nutraceuticals and scientific claims substantiation, having served as a Research Physician at a prominent New York-based university where he evaluated therapeutics and emerging healthcare technologies.
The agreement aligns with Synbio’s broader strategy of building a diversified healthcare company. It pairs near-term revenue from commercial wellness products with longer-term value creation from its AI-driven mental health technologies. Synbio is developing an AI-driven software that screens for mental health conditions using facial analysis. While that technology advances through clinical validation, the nutraceutical line is expected to generate early revenue through direct-to-consumer online sales, which the company plans to launch in 2026.
This dual-track approach provides multiple avenues for growth. The immediate revenue from nutraceutical sales can support continued investment in innovation, reducing the financial pressure typically associated with tech development. For a company with a limited operating history, this strategy may enhance its ability to attract investors and partners by demonstrating a clear path to commercial viability.
However, forward-looking statements in the press release caution that actual results may differ due to risks such as dependence on third parties, market conditions, and the availability of capital. The company also notes that it does not undertake to update any forward-looking statements.
In summary, Synbio’s licensing agreement is a calculated step toward establishing a revenue base while its core AI technology matures. By leveraging the scientific expertise of MD PHD Wellness, Synbio aims to enter the competitive nutraceutical market with credible products, potentially improving its financial stability and market position.
